We will often recommend a multidisciplinary approach incorporating biological, psychosocial, and cultural treatment practices . The CEO, Dr. Hassamal, is an active research investigator and has extensive experience prescribing cutting edge pharmacotherapeutics, digital technologies, and neuromodulation treatments.
At the California Neuropsychiatric Institute, we specialize in assessing and treating the whole spectrum of mental health conditions, including treatment resistant cases. Newly approved drugs by the FDA Spravato and evidence-based pharmacotherapies are an integral part of the treatment plan.
